Role of silymarin to treat fibrosis development in non-alcoholic fatty liver disease

Hepatology Research

Volumn 41, Issue 7, 2011, Pages 668-

  Abenavoli, Ludovico ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; SILYMARIN;

ANTIOXIDANT ACTIVITY; BODY MASS; DRUG MECHANISM; HUMAN; INSULIN RESISTANCE; LETTER; LIPID PEROXIDATION; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; MEDICINAL PLANT; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL;

EID: 79959794577     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2011.00823.x     Document Type: Letter

References (5)

1. Hojo M, Watanabe S. Pharmacological therapy of nonalcoholic steatohepatitis. Hepatol Res 2011; 41: 209-16.
2. Urtasun R, Conde de la Rosa L, Nieto N. Oxidative and nitrosative stress and fibrogenic response. Clin Liver Dis 2008; 12: 769-90.
3. Czaja MJ. Cell signaling in oxidative stress-induced liver injury. Semin Liver Dis 2007; 27: 378-89.
4. Abenavoli L, Capasso R, Milic N etal. Milk thistle in liver diseases: past, present, future. Phytother Res 2010; 24: 1423-32.
5. Loguercio C, Federico A, Trappoliere M etal. The effect of a silybin-vitamin e-phospholipid complex on non-alcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007; 52: 2387-95.